Publications by authors named "Sudarshan R Iyer"
ROS1 is the largest receptor tyrosine kinase in the human genome. Rearrangements of the ROS1 gene result in oncogenic ROS1 kinase fusion proteins that are currently the only validated biomarkers for targeted therapy with ROS1 TKIs in patients. While numerous somatic missense mutations in ROS1 exist in the cancer genome, their impact on catalytic activity and pathogenic potential is unknown.
View Article and Find Full Text PDFArticle Synopsis
- Targeted therapy for ROS1-fusion-driven non-small cell lung cancer (NSCLC) is effective, but about 19% of patients develop resistance due to MYC amplification.* -
- Research using a patient-derived cell line demonstrated that MYC overexpression leads to significant resistance against ROS1-targeted therapy, necessitating combination treatments for better efficacy.* -
- The study suggests combining ROS1 inhibitors with CDK4/6 inhibitors and mitochondrial inhibitors as potential strategies to overcome resistance and improve tumor control in NSCLC patients.*
Purpose: Gliomas, a genetically heterogeneous group of primary central nervous system tumors, continue to pose a significant clinical challenge. Discovery of chromosomal rearrangements involving kinase genes has enabled precision therapy, and improved outcomes in several malignancies.
Experimental Design: Positing that similar benefit could be accomplished for patients with brain cancer, we evaluated The Cancer Genome Atlas (TCGA) glioblastoma dataset.